SAFIR01: steps towards precision treatment in breast cancer
Mené en France à partir de l'analyse moléculaire de biopsies de métastases prélevées sur 407 patientes atteintes d'un cancer du sein, cet essai prospectif identifie des altérations génétiques individuelles et évalue la proportion de patientes pouvant recevoir un traitement ciblé
Progress in cancer genomics has raised hopes of increased precision in the identification of patients suitable for targeted therapies tailored to their genotypes. Effective implementation of such precision medicine will need to take into account diversity between and within tumours to mitigate tumour evolution through space and time.
In The Lancet Oncology, Fabrice André and colleagues3 report results from the SAFIR01 breast cancer trial, which provide important insights into the logistical, scientific, and clinical challenges of implementing national cancer genomic assessment. The primary purpose of SAFIR01 was to investigate the feasibility of molecular screening to identify potential candidates for entry into phase 1 and 2 trials, rather than to assess the direct clinical benefits of the therapies for patients after screening. The steering committee judged molecular screening would be of insufficient value if the proportion of patients recruited into targeted studies was lower than 30%...
The Lancet Oncology , résumé, 2013